康希诺生物(06185.HK)受政府委托加紧开展新冠病毒疫苗与检测试剂研发
天津国际生物医药联合研究院公布,天津市科技局1月28日出台「新型冠状病毒感染应急防治」科技重大专项。研究院孵化毕业企业康希诺生物(06185.HK)、丹娜(天津)生物科技受市专项委托,分别牵头实施开展「新型冠状病毒疫苗」和「侵袭性真菌病系列早期检测试剂盒」研发工作。两企业同时获滨海新区应急科技专项支持,加紧研发短期内可投入临床应用的技术产品,解决新型冠状病毒感染肺炎相关诊疗问题。
康希诺生物主要承担新冠病毒疫苗和临床前评价研发任务,开展快速满足应急的多种疫苗技术的评价,研发病毒载体疫苗、mRNA疫苗、重组蛋白疫苗等关键技术。丹娜生物基於此前对SARS病毒感染肺炎合并侵袭性真菌感染成为患者死亡的重要原因相关研究,开展对新型冠状病毒和侵袭性真菌合并感染进行联合检测的试剂研发。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.